TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing

Teva reports Q2 revenue decline to $4.1B but raises outlook for key innovative brands due to strong growth (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $TEVA

Read the full article at SEC EDGAR

More Regulatory news